Nanomedicine: Clinical applications of polyethylene glycol conjugated proteins and drugs

Clinical Pharmacokinetics

Volumn 45, Issue 10, 2006, Pages 965-988

  Parveen, Suphiya ^a   Sahoo, Sanjeeb K ^a  

^a INSTITUTE OF LIFE SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; AP 5280; AP 5346; ASPARAGINASE; ASPARAGINASE MACROGOL; CAMPTOTHECIN; CD 870; CERTOLIZUMAB PEGOL; CT 2106; DEAMINASE; FCE 28068; FCE 28069; GLUTADON; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; HEPACID; HUMAN GROWTH HORMONE; MACROGOL; MELANOCID; PACLITAXEL POLIGLUMEX; PEGADEMASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGVISOMANT; PNU 166148; PNU 166945; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STIMALMER; UNCLASSIFIED DRUG; UNINDEXED DRUG; URATE OXIDASE; ZINOSTATIN;

ACROMEGALY; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CLINICAL TRIAL; CROHN DISEASE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; HEPATITIS C; HUMAN; KIDNEY CARCINOMA; MEDICAL LITERATURE; MELANOMA; MOLECULAR DYNAMICS; MULTIPLE MYELOMA; NANOTECHNOLOGY; NEUTROPENIA; PHYSICAL CHEMISTRY; POLYMERIZATION; PRIORITY JOURNAL;

CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; HUMANS; NANOTECHNOLOGY; PHARMACEUTIC AIDS; PHARMACEUTICAL PREPARATIONS; POLYETHYLENE GLYCOLS; PROTEINS;

EID: 33748918574     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200645100-00002     Document Type: Article

References (181)

1. Winau F, Westphal O, Winau R. Paul Ehrlich: in search of the magic bullet. Microbes Infect 2004; 6: 786-9
2. Sahoo SK. Applications of nanomedicine. Asia Pacific Biotech News 2005; 9: 1048-50
3. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003; 2: 347-60
4. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002; 2: 750-63
5. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005; 4: 145-60
6. Shaffer C. Nanomedicine transforms drug delivery. Drug Discov Today 2005; 10: 1581-2
7. Freitas Jr RA. What is nanomedicine? Dis Mon 2005; 51: 325-41
8. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J 2005; 19: 311-30
9. Thanou M, Duncan R. Polymer-protein and polymer-drug conjugates in cancer therapy. Curr Opin Investig Drugs 2003; 4: 701-9
10. Kayser O, Lemke A, Hernandez-Trejo N. The impact of nanobiotechnology on the development of new drug delivery systems. Curr Pharm Biotechnol 2005; 6: 3-5
11. Mainardes RM, Silva LP. Drug delivery systems: past, present, and future. Curr Drug Targets 2004; 5: 449-55
12. Hamman JH, Enslin GM, Kotze AF. Oral delivery of peptide drugs: barriers and developments. BioDrugs 2005; 19: 165-77
13. Pawar R, Ben-Ari A, Domb AJ. Protein and peptide parenteral controlled delivery. Expert Opin Biol Ther 2004; 4: 1203-12
14. Orive G, Hernandez RM, Rodriguez Gascon A, et al. Drug delivery in biotechnology: present and future. Curr Opin Biotechnol 2003; 14: 659-64
15. Brown LR. Commercial challenges of protein drug delivery. Expert Opin Drug Deliv 2005; 2: 29-42
16. Sato H, Sugiyama Y, Tsuji A, et al. Importance of receptor-mediated endocytosis in peptide delivery and targeting: kinetic aspects. Adv Drug Deliv Rev 1996; 19: 445-67
17. Hashida M, Nishikawa M, Yamashita F, et al. Cell-specific delivery of genes with glycosylated carriers. Adv Drug Deliv Rev 2001; 52: 187-96
18. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000; 11: 265-83
19. Links M, Brown R. Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs. Expert Rev Mol Med 1999; 1999: 1-21
20. Abuchowski A, McCoy JR, Palczuk NC, et al. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 1977; 252: 3582-6
21. Conti S, Polonelli L, Frazzi R, et al. Controlled delivery of biotechnological products. Curr Pharm Biotechnol 2000; 1: 313-23
22. Qiu LY, Bae YH. Polymer architecture and drug delivery. Pharm Res 2006; 23: 1-30
23. Kumar MN, Kumar N. Polymeric controlled drug-delivery systems: perspective issues and opportunities. Drug Dev Ind Pharm 2001; 27: 1-30
24. Kanjickal DG, Lopina ST. Modeling of drug release from polymeric delivery systems: a review. Crit Rev Ther Drug Carrier Syst 2004; 21: 345-86
25. Torchilin VP, Trubetskoy VS. Which polymers can make nanoparticulate drug carriers long-circulating? Adv Drug Deliv Rev 1995; 16: 141-55
26. Torchilin VP. Polymer-coated long-circulating microparticulate pharmaceuticals. J Microencapsul 1998; 15: 1-19
27. Hoste K, De Winne K, Schacht E. Polymeric prodrugs. Int J Pharm 2004; 277: 119-31
28. Gref R, Minamitake Y, Peracchia MT, et al. Biodegradable long-circulating polymeric nanospheres. Science 1994; 263: 1600-3
29. Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001; 40: 539-51
30. Delgado C, Francis GE, Fisher D. The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 1992; 9: 249-304
31. Abuchowski A, van Es T, Palczuk NC, et al. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 1977; 252: 3578-81
32. Molineux G. Pegylation: engineering improved pharmaceuticals for enhanced therapy. Cancer Treat Rev 2002; 28 Suppl. A: 13-6
33. Yowell SL, Blackwell S. Novel effects with polyethylene glycol modified pharmaceuticals. Cancer Treat Rev 2002; 28 Suppl. A: 3-6
34. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev 2001; 46: 169-85
35. Vasey PA, Kaye SB, Morrison R, et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res 1999; 5: 83-94
36. Huang PS, Oliff A. Drug-targeting strategies in cancer therapy. Curr Opin Genet Dev 2001; 11: 104-10
37. Seymour LW, Ferry DR, Anderson D, et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 2002; 20: 1668-76
38. Duncan R, Seymour LC, Scarlett L, et al. Fate of N-(2-hydroxypropyl) methacrylamide copolymers with pendent galactosamine residues after intravenous administration to rats. Biochim Biophys Acta 1986; 880: 62-71
39. Meerum Terwogt JM, ten Bokkel Huinink WW, Schellens JH, et al. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs 2001; 12: 315-23
40. Rice JR, Howell SB. AP-5346 polymer-delivered platinum complex. Drugs Future 2004; 29: 561-5
41. Gianasi E, Buckley RG, Latigo J, et al. HPMA copolymers platinates containing dicarboxylato ligands: preparation, characterisation and in vitro and in vivo evaluation. J Drug Target 2002; 10: 549-56
42. Gianasi E, Wasil M, Evagorou EG, et al. HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo. Eur J Cancer 1999; 35: 994-1002
43. Schoemaker NE, van Kesteren C, Rosing H, et al. A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin. Br J Cancer 2002; 87: 608-14
44. Garfield D. New form of paclitaxel shows promise. Lancet Oncol 2001; 2: 192
45. Li C, Yu DF, Newman RA, et al. Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate. Cancer Res 1998; 58: 2404-9
46. Nemunaitis J, Cunningham C, Senzer N, et al. Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors. Cancer Invest 2005; 23: 671-6
47. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003; 2: 214-21
48. Mehvar R. Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. J Pharm Pharm Sci 2000; 3: 125-36
49. Veronese FM, Harris JM. Introduction and overview of peptide and protein pegylation. Adv Drug Deliv Rev 2002; 54: 453-6
50. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 2002; 54: 459-76
51. Yamaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharm Sci 1994; 83: 601-6
52. Yamaoka T, Tabata Y, Ikada Y. Fate of water-soluble polymers administered via different routes. J Pharm Sci 1995; 84: 349-54
53. Friman S, Egestad B, Sjovall J, et al. Hepatic excretion and metabolism of polyethylene glycols and mannitol in the cat. J Hepatol 1993; 17: 48-55
54. Kawai F. Microbial degradation of polyethers. Appl Microbiol Biotechnol 2002; 58: 30-8
55. Wieder KJ, Palczuk NC, van Es T, et al. Some properties of polyethylene glycol: phenylalanine ammonia-lyase adducts. J Biol Chem 1979; 254: 12579-87
56. Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 2002; 54: 531-45
57. Boccu E, Velo GP, Veronese FM. Pharmacokinetic properties of polyethylene glycol derivatized superoxide dismutase. Pharmacol Res Commun 1982; 14: 113-20
58. Beauchamp CO, Gonias SL, Menapace DP, et al. A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alpha 2-macroglobulin. Anal Biochem 1983; 131: 25-33
59. Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2003; 55: 1261-77
60. Zalipsky S. Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates. Bioconjug Chem 1995; 6: 150-65
61. Francis GE, Fisher D, Delgado C, et al. PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques. Int J Hematol 1998; 68: 1-18
62. Cunningham-Rundles C, Zhuo Z, Griffith B, et al. Biological activities of polyethylene-glycol immunoglobulin conjugates: resistance to enzymatic degradation. J Immunol Methods 1992; 152: 177-90
63. Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65: 271-84
64. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 6387-92
65. Hershfield MS, Buckley RH, Greenberg ML, et al. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med 1987; 316: 589-96
66. Ho DH, Brown NS, Yen A, et al. Clinical pharmacology of polyethylene glycol-L-asparaginase. Drug Metab Dispos 1986; 14: 349-52
67. Muss HB, Spell N, Scudiery D, et al. A phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkins lymphoma. Invest New Drugs 1990; 8: 125-30
68. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673-80
69. Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000; 68: 556-67
70. Yasuda Y, Fujita T, Takakura Y, et al. Biochemical and biopharmaceutical properties of macromolecular conjugates of uricase with dextran and polyethylene glycol. Chem Pharm Bull (Tokyo) 1990; 38: 2053-6
71. Muller AF, Kopchick JJ, Flyvbjerg A, et al. Clinical review 166: Growth hormone receptor antagonists. J Clin Endocrinol Metab 2004; 89: 1503-11
72. Kramer GC. Counterintuitive red blood cell substitute: polyethylene glycol-modified human hemoglobin. Crit Care Med 2003; 31: 1882-4
73. Maher S, Toomey D, Condron C, et al. Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. Immunol Cell Biol 2002; 80: 131-7
74. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-65
75. Daniel PT, Scholz C, Westermann J, et al. Dendritic cells prevent CD95 mediated T lymphocyte death through costimulatory signals. Adv Exp Med Biol 1998; 451: 173-7
76. Restifo NP. Not so Fas: re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med 2000; 6: 493-5
77. Walker PR, Saas P, Dietrich PY. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol 1997; 158: 4521-4
78. von Bernstorff W, Spanjaard RA, Chan AK, et al. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand. Surgery 1999; 125: 73-84
79. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells: a mechanism of immune evasion? Nat Med 1996; 2: 1361-6
80. O'Connell J, O'Sullivan GC, Collins JK, et al. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075-82
81. Niehans GA, Brunner T, Frizelle SP, et al. Human lung carcinomas express Fas ligand. Cancer Res 1997; 57: 1007-12
82. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274: 1363-6
83. Friesen C, Fulda S, Debatin KM. Cytotoxic drugs and the CD95 pathway. Leukemia 1999; 13: 1854-8
84. Rihova B, Strohalm J, Hoste K, et al. Immunoprotective therapy with targeted anticancer drugs. Macromol Symp 2001; 172: 21-8
85. Ringsdorf H. Structure and properties of pharmacologically active polymers. J Polym Sci Symp 1975; 51: 135-53
86. Duncan R. Drug-polymer conjugates: potential for improved chemotherapy. Anticancer Drugs 1992; 3: 175-210
87. Jain RK. The next frontier of molecular medicine: delivery of therapeutics. Nat Med 1998; 4: 655-7
88. Petrak K. Essential properties of drug-targeting delivery systems. Drug Discov Today 2005; 10: 1667-73
89. Takakura Y, Takagi A, Hashida M, et al. Disposition and tumor localization of mitomycin C-dextran conjugates in mice. Pharm Res 1987; 4: 293-300
90. Veronese FM, Morpurgo M. Bioconjugation in pharmaceutical chemistry. Farmaco 1999; 54: 497-516
91. Kawaguchi T, Asakawa H, Tashiro Y, et al. Stability, specific binding activity, and plasma concentration in mice of an oligodeoxynucleotide modified at 5′-terminal with poly(ethylene glycol). Biol Pharm Bull 1995; 18: 474-6
92. Herman S, Hooftman G, Schacht E. Poly (ethylene glycol) with reactive endgroups: I - modification of proteins. J Bioact Compat Polym 1995; 10: 145-87
93. Veronese FM. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 2001; 22: 405-17
94. Sato H. Enzymatic procedure for site-specific pegylation of proteins. Adv Drug Deliv Rev 2002; 54: 487-504
95. Jaschke A, Furste JP, Nordhoff E, et al. Synthesis and properties of oligodeoxyribonucleotide-polyethylene glycol conjugates. Nucleic Acids Res 1994; 22: 4810-7
96. Tarasow TM, Tinnermeier D, Zyzniewski C. Characterization of oligodeoxyribonucleotide-polyethylene glycol conjugates by electrospray mass spectrometry. Bioconjug Chem 1997; 8: 89-93
97. Greish K, Fang J, Inutsuka T, et al. Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clin Pharmacokinet 2003; 42: 1089-105
98. Caliceti P, Monfardini C, Sartore L, et al. Preparation and properties of monomethoxy poly(ethylene glycol) doxorubicin conjugates linked by an amino acid or a peptide as spacer. Farmaco 1993; 48: 919-32
99. Levy Y, Hershfield MS, Fernandez-Mejia C, et al. Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase. J Pediatr 1988; 113: 312-7
100. Graham ML. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev 2003; 55: 1293-302
101. Reddy KR, Modi MW, Pedder S. Use of peginterferon a-2a (40 KD) (Pegasys®) for the treatment of hepatitis C. Adv Drug Deliv Rev 2002; 54: 571-86
102. Wang YS, Youngster S, Grace M, et al. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev 2002; 54: 547-70
103. Bukowski R, Ernstoff MS, Gore ME, et al. Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. J Clin Oncol 2002; 20: 3841-9
104. Heil G, Hoelzer D, Sanz MA, et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 1997; 90: 4710-8
105. Holmes FA, Jones SE, O'Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002; 13: 903-9
106. Kinstler O, Molineux G, Treuheit M, et al. Mono-N-terminal poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2002; 54: 477-85
107. Vellard M. The enzyme as drug: application of enzymes as pharmaceuticals. Curr Opin Biotechnol 2003; 14: 1-7
108. Vicent MJ, Duncan R. Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol 2006; 24: 39-47
109. Clark R, Olson K, Fuh G, et al. Long-acting growth hormones produced by conjugation with polyethylene glycol. J Biol Chem 1996; 271: 21969-77
110. Drake WM, Trainer PJ. Clinical use of pegvisomant for the treatment of acromegaly. Treat Endocrinol 2003; 2: 369-74
111. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005; 129: 807-18
112. Chapman AP, Antoniw P, Spitali M, et al. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol 1999; 17: 780-3
113. Conover CD, Linberg R, Gilbert CW, et al. Effect of polyethylene glycol conjugated bovine hemoglobin in both top-load and exchange transfusion rat models. Artif Organs 1997; 21: 1066-75
114. Bomalaski JS, Holtsberg FW, Ensor CM, et al. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. J Rheumatol 2002; 29: 1942-9
115. Greenwald RB, Choe YH, McGuire J, et al. Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev 2003; 55: 217-50
116. Greenwald RB, Gilbert CW, Pendri A, et al. Drug delivery systems: water soluble taxol 2′-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. J Med Chem 1996; 39: 424-31
117. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002; 22: 143-52
118. Filbey JA, Charles SA. Shellac to pegylation: 2500 years of polymers in controlled release drug delivery. Drug Delivery Technology 2005; 5: 65-9
119. Haffner ME. The Food and Drug Administration's Office of Orphan Products Development: incentives, grants, and special designations speed therapies for orphan diseases. Retina 2005; 25: S89-90
120. Mashburn LT, Wriston Jr JC. Tumor inhibitory effect of L-asparaginase from escherichia coli. Arch Biochem Biophys 1964; 105: 450-2
121. Soares AL, Guimaraes GM, Polakiewicz B, et al. Effects of polyethylene glycol attachment on physicochemical and biological stability of E. coli L-asparaginase. Int J Pharm 2002; 237: 163-70
122. Sawa T, Sahoo SK, Maeda H. Water-soluble polymer therapeutics with a special emphasis on cancer chemotherapy. In: Arshady R, editor. Polymeric biomaterials, the PBM series, volume 1: introduction to polymeric biomaterials. London: Citus Books, 2003: 233-61
123. Glue P, Rouzier-Panis R, Raffanel C, et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology 2000; 32: 647-53
124. Bowen S, Tare N, Inoue T, et al. Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-timulating factor mutein. Exp Hematol 1999; 27: 425-32
125. Satake-Ishikawa R, Ishikawa M, Okada Y, et al. Chemical modification of recombinant human granulocyte colony-stimulating factor by polyethylene glycol increases its biological activity in vivo. Cell Struct Funct 1992; 17: 157-60
126. Paisley AN, Drake WM. Treatment of pituitary tumors: pegvisomant. Endocrine 2005; 28: 111-4
127. Nucci ML, Olejarczyk J, Abuchowski A. Immunogenicity of polyethylene glycol-modified superoxide dismutase and catalase. J Free Radic Biol Med 1986; 2: 321-5
128. Pyatak PS, Abuchowski A, Davis FF. Preparation of a polyethylene glycol: superoxide dismutase adduct, and an examination of its blood circulation life and anti-inflammatory activity. Res Commun Chem Pathol Pharmacol 1980; 29: 113-27
129. Muizelaar JP. Clinical trials with Dismutec (pegorgotein; polyethylene glycol-conjugated superoxide dismutase; PEG-SOD) in the treatment of severe closed head injury. Adv Exp Med Biol 1994; 366: 389-400
130. Muizelaar JP, Marmarou A, Young HF, et al. Improving the outcome of severe head injury with the oxygen radical scavenger polyethylene glycol-conjugated superoxide dismutase: a phase II trial. J Neurosurg 1993; 78: 375-82
131. Feldmann M, Maini RN. Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. Joint Bone Spine 2002; 69: 12-8
132. Sandborn WJ. Strategies for targeting tumour necrosis factor in IBD. Best Pract Res Clin Gastroenterol 2003; 17: 105-17
133. Beutler E, Gelbart T. Glucocerebrosidase (Gaucher disease). Hum Mutat 1996; 8: 207-13
134. Linberg R, Conover CD, Shum KL, et al. Increased tissue oxygenation and enhanced radiation sensitivity of solid tumors in rodents following polyethylene glycol conjugated bovine hemoglobin administration. In Vivo 1998; 12: 167-73
135. Davis S, Park YK, Abuchowski A, et al. Hypouricaemic effect of polyethyleneglycol modified urate oxidase. Lancet 1981; II: 281-3
136. Lerchen HG. Camptothecin antitumor agents. IDrugs 1999; 2: 896-906
137. Helene C. The anti-gene strategy: control of gene expression by triplex-forming-oligonucleotides. Anticancer Drug Des 1991; 6: 569-84
138. Gold L. Oligonucleotides as research, diagnostic, and therapeutic agents. J Biol Chem 1995; 270: 13581-4
139. Langer CJ. CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes. Clin Lung Cancer 2004; 6 Suppl. 2: S85-8
140. Siddiqui MA, Keating GM. Pegaptanib: in exudative age-related macular degeneration. Drugs 2005; 65: 1571-7
141. Fraunfelder FW. Pegaptanib for wet macular degeneration. Drugs Today (Barc) 2005; 41: 703-9
142. Luo Y, Prestwich GD. Cancer-targeted polymeric drugs. Curr Cancer Drug Targets 2002; 2: 209-26
143. Yokoyama M. Drug targeting with nano-sized carrier systems. J Artif Organs 2005; 8: 77-84
144. Maeda H, Seymour LW, Miyamoto Y. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug Chem 1992; 3: 351-62
145. Torchilin VP. Drug targeting. Eur J Pharm Sci 2000; 11 Suppl. 2: S81-91
146. Au JL, Jang SH, Zheng J, et al. Determinants of drug delivery and transport to solid tumors. J Control Release 2001; 74: 31-46
147. Langer R. Drug delivery and targeting. Nature 1998; 392: 5-10
148. Modi S, Jain JP, Kumar N. Polymer-drug conjugates: recent development for anticancer drugs. CRIPS 2004; 5 (2): 2-8
149. Monsky WL, Fukumura D, Gohongi T, et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res 1999; 59: 4129-35
150. Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A 1998; 95: 4607-12
151. Yuan F, Salehi HA, Boucher Y, et al. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res 1994; 54: 4564-8
152. Dellian M, Witwer BP, Salehi HA, et al. Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment. Am J Pathol 1996; 149: 59-71
153. Maeda H, Fang J, Inutsuka T, et al. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol 2003; 3: 319-28
154. Muggia FM. Doxorubicin-polymer conjugates: further demonstration of the concept of enhanced permeability and retention. Clin Cancer Res 1999; 5: 7-8
155. Duncan R. Polymer conjugates for tumour targeting and intra-cytoplasmic delivery. The EPR effect as a common gateway? Pharm Sci Technol Today 1999; 2: 441-9
156. Fang J, Sawa T, Maeda H. Factors and mechanism of 'EPR' effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. Adv Exp Med Biol 2003; 519: 29-49
157. Gleave ME, Coupland D, Drachenberg D, et al. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology 1996; 47: 708-12
158. Garzotto M, Hudson RG, Peters L, et al. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL. Cancer 2003; 98: 1417-22
159. Caplan A, Kratz A. Prostate-specific antigen and the early diagnosis of prostate cancer. Am J Clin Pathol 2002; 117 Suppl.: S104-8
160. Sahoo SK, Labhasetwar V. Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm 2005; 2: 373-83
161. Sahoo SK, Ma W, Labhasetwar V. Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer 2004; 112: 335-40
162. Lamprecht A, Ubrich N, Yamamoto H, et al. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther 2001; 299: 775-81
163. Scherer F, Anton M, Schillinger U, et al. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther 2002; 9: 102-9
164. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004; 10: 415-27
165. Fonsatti E, Altomonte M, Arslan P, et al. Endoglin (CD105): a target for anti-angiogenetic cancer therapy. Curr Drug Targets 2003; 4: 291-6
166. Molema G, Meijer DK, de Leij LF. Tumor vasculature targeted therapies: getting the players organized. Biochem Pharmacol 1998; 55: 1939-45
167. Stevanovic S. Identification of tumour-associated T-cell epitopes for vaccine development. Nat Rev Cancer 2002; 2: 514-20
168. Juretic A, Spagnoli GC, Schultz-Thater E, et al. Cancer/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies. Lancet Oncol 2003; 4: 104-9
169. Vasir JK, Labhasetwar V. Targeted drug delivery in cancer therapy. Technol Cancer Res Treat 2005; 4: 363-74
170. Schally AV, Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab 2004; 15: 300-10
171. Weiner LM. Fully human therapeutic monoclonal antibodies. J Immunother 2006; 29: 1-9
172. Trail PA, Willner D, Lasch SJ, et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 1993; 261: 212-5
173. Okamoto K, Yamaguchi T, Otsuji E, et al. Targeted chemotherapy in mice with peritoneally disseminated gastric cancer using monoclonal antibody-drug conjugate. Cancer Lett 1998; 122: 231-6
174. Remsen LG, Trail PA, Hellstrom I, et al. Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model. Neurosurgery 2000; 46: 704-9
175. Wakai Y, Matsui J, Koizumi K, et al. Effective cancer targeting using an anti-tumor tissue vascular endothelium-specific monoclonal antibody (TES-23). Jpn J Cancer Res 2000; 91: 1319-25
176. Sartore L, Caliceti P, Schiavon O, et al. Accurate evaluation method of the polymer content in monomethoxy(polyethylene glycol) modified proteins based on amino acid analysis. Appl Biochem Biotechnol 1991; 31: 213-22
177. Snyder SL, Sobocinski PZ. An improved 2,4,6-trinitrobenzene-sulfonic acid method for the determination of amines. Anal Biochem 1975; 64: 284-8
178. Habeeb AF. Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Anal Biochem 1966; 14: 328-36
179. Choe YH, Conover CD, Wu D, et al. Anticancer drug delivery systems: multi-loaded N4-acyl poly(ethylene glycol) prodrugs of ara-C: II. efficacy in ascites and solid tumors. J Control Release 2002; 79: 55-70
180. Monfardini C, Schiavon O, Caliceti P, et al. A branched monomethoxypoly(ethylene glycol) for protein modification. Bioconjug Chem 1995; 6: 62-9
181. Ono K, Kai Y, Maeda H, et al. Selective synthesis of 2,4-bis(O- methoxypolyethylene glycol)-6-chloro-s-triazine as a protein modifier. J Biomater Sci Polym Ed 1991; 2: 61-5